Genmab A/S (NASDAQ:GMAB – Get Free Report)‘s stock had its “underweight” rating restated by stock analysts at Morgan Stanley in a research note issued on Tuesday, Benzinga reports.
A number of other analysts also recently issued reports on GMAB. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, March 6th. Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. UBS Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, December 6th. Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Tuesday. Finally, BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Hold” and an average price target of $48.50.
Get Our Latest Analysis on GMAB
Genmab A/S Stock Down 1.6 %
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.34 by $0.02. The firm had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, sell-side analysts anticipate that Genmab A/S will post 1.09 earnings per share for the current fiscal year.
Institutional Trading of Genmab A/S
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Alliancebernstein L.P. lifted its position in Genmab A/S by 21.0% in the 2nd quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock valued at $311,210,000 after purchasing an additional 1,420,915 shares during the last quarter. Millennium Management LLC raised its position in Genmab A/S by 655.9% during the fourth quarter. Millennium Management LLC now owns 919,408 shares of the company’s stock valued at $38,965,000 after buying an additional 797,770 shares during the period. Envestnet Asset Management Inc. increased its stake in shares of Genmab A/S by 93.6% in the third quarter. Envestnet Asset Management Inc. now owns 946,880 shares of the company’s stock worth $33,396,000 after acquiring an additional 457,772 shares during the last quarter. Morgan Stanley lifted its stake in Genmab A/S by 40.1% in the fourth quarter. Morgan Stanley now owns 1,215,861 shares of the company’s stock valued at $51,528,000 after acquiring an additional 347,824 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of Genmab A/S by 11.1% in the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after buying an additional 347,437 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Recommended Stories
- Five stocks we like better than Genmab A/S
- Technology Stocks Explained: Here’s What to Know About Tech
- Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
- What is the Euro STOXX 50 Index?
- Delta Airline’s Put Option Activity Isn’t Bad News
- Bank Stocks – Best Bank Stocks to Invest In
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.